Sonic Foundry Announces Delisting From Nasdaq

Sonic Foundry, Inc. (NASDAQ:SOFO), the trusted leader in developing comprehensive video recording and streaming solutions for corporations, health organizations and government entities today announced that the Company

Sonic Foundry, Inc. (NASDAQ:SOFO), the trusted leader in developing comprehensive video recording and streaming solutions for corporations, health organizations and government entities today announced that the Company received a final delisting notice from Nasdaq on December 1, 2023. The delisting is a result of failure to satisfy the $1.00 minimum bid price listing requirement in Nasdaq Listing Rule 5550(a)(2) and failure to comply with Nasdaq’s $2,500,000 minimum stockholders’ equity requirement for continued listing or any of the alternative requirements in Listing Rule 5550(b). Suspension of trading in the Company’s common stock on the Nasdaq exchange will be effective at the open of trading on December 5, 2023.

Sonic Foundry CEO Joe Mozden, Jr. commented, “While we are disappointed in the Nasdaq delisting, this does not deter us from our long-term strategy of transforming Sonic Foundry into a high-growth company by launching new businesses and services. To that end, we are excited about the progress we have made with our newest businesses, Global Learning Exchange™ and Vidable®. Each addresses real-world challenges in their respective markets where we continue to draw interest from prospects and are now starting to secure our first contracts.”

The Company expects its common stock will commence trading on the OTC Markets Group platform at the open of trading on December 5, 2023, under the symbol “SOFO” and the Company plans to apply to trade on the OTCQB Market or other OTC market in the coming weeks.

Total
0
Shares
Related Posts
Read More

Drugs for Neglected Diseases Initiative and Sanofi Announced Treatment Success Rates of Up to 95% From a Phase II/II Study Investigating the Safety and Efficacy of Single-dose Acoziborole for Sleeping Sickness

The Drugs for Neglected Diseases initiative (DNDi) and Sanofi announce treatment success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole, a potentially transformative investigational treatment for sleeping sickness, published today in The Lancet Infectious Diseases medical journal.

SNY

Read More

Apparel Retailer Express Files for Bankruptcy; Shuts Some Stores

Express Inc (OTC:EXPR) and subsidiaries file Chapter 11 petitions, signaling a strategic move to optimize operations and strengthen financial position. The retailer plans to shutter 95 stores, including all UpWest outlets, with a commitment of $35 million in new financing. Amidst this restructuring, Express receives $49 million from the IRS and eyes a potential majority stake sale to WHP Global-led consortium.

EXPR